Associated Papers
The Cytochrome P450 2C8*3 Variant (rs11572080) Is Associated with Improved Asthma Symptom Control in Children and Altered Lipid Mediator Production and Inflammatory Response in Human Bronchial Epithelial Cells.
Almestica-Roberts M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
A comprehensive analysis of germline predisposition to early-onset ovarian cancer.
Horackova K et al.
Scientific Reports, 2024
Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences.
Camara MD et al.
Human Genomics, 2024
Functional Characterization of Allelic Variations of Human Cytochrome P450 2C8 (V181I, I244V, I331T, and L361F).
Lee YB et al.
International Journal of Molecular Sciences, 2023
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.
Milovanovic DD et al.
Balkan Journal of Medical Genetics : Bjmg, 2016
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Backman JT et al.
Pharmacological Reviews, 2016
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8.
Jiang H et al.
Amino Acids, 2011
Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
Hanioka N et al.
Basic & Clinical Pharmacology & Toxicology, 2010
Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions.
Gao Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2010
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
Daily EB et al.
Pharmacogenomics, 2009
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H et al.
Basic & Clinical Pharmacology & Toxicology, 2009
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.
Saito Y et al.
Pharmacogenetics and Genomics, 2007
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
Nakajima Y et al.
Clinical Pharmacology and Therapeutics, 2006
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.
García-Martín E et al.
Molecular Diagnosis & Therapy, 2006
Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.
Hichiya H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005